ClinicalTrials.gg
CompletedNCT04210115Updated Oct 30, 2026

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

A Phase 3 interventional study of pembrolizumab and placebo in Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC) and Esophageal Adenocarcinoma (EAC), sponsored by Merck Sharp & Dohme LLC. Completed at 170 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Updated Oct 30, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
703
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing pembrolizumab in Esophageal Squamous Cell Carcinoma — 5 open to participants now, 6 under way, 2 of them phase 3. pembrolizumab · Esophageal Squamous Cell Carcinoma.

Enrollment
Largest of 17
703 · median 50
Started
2020
with 3 others
Phase 3
2 of 17
1 open now
Registered
6th of 17
by date
Lead sponsor
1 of 17
Merck Sharp & Dohme LLC

Among the 17 studies testing pembrolizumab in Esophageal Squamous Cell Carcinoma, this one has the largest enrollment, is one of 4 that started in 2020, is one of 2 in phase 3, and was the 6th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

5 of the 17 studies testing pembrolizumab in Esophageal Squamous Cell Carcinoma are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing pembrolizumab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Event-free Survival (EFS) and Overall Survival (OS) in:

  • participants whose tumors express Programmed Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10
  • participants whose tumors express PD-L1 CPS ≥1
  • all participants

The primary study hypotheses are that dCRT+ pembrolizumab is better than dCRT + placebo with respect to:

  • EFS in participants whose tumors express PD-L1 CPS ≥10
  • EFS in participants whose tumors express PD-L1 CPS ≥1
  • EFS in all participants
  • OS in participants whose tumors express PD-L1 CPS ≥10
  • OS in participants whose tumors express PD-L1 CPS ≥1
  • OS in all participants
Read the detailed description

Participants receive pembrolizumab or placebo PLUS one of two chemotherapy regimens PLUS radiation therapy for up to approximately one year. The chemotherapy regimens are either:

  • FP (5-fluorouracil [5-FU] + cisplatin) or
  • FOLFOX (5-FU + oxaliplatin + leucovorin or levoleucovorin).
03

Conditions studied

  • Esophageal Squamous Cell Carcinoma (ESCC)
  • Gastroesophageal Junction Carcinoma (GEJC)
  • Esophageal Adenocarcinoma (EAC)

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
  • Programmed Death-Ligand 2 (PDL2, PD-L2)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has or cytologically confirmed diagnosis of CTX N+ M0 or cT2-T4a NX M0 ESCC, GEJC, EAC, or histologically or cytologically confirmed diagnosis of cTX N+ M1 cervical or upper thoracic esophageal carcinoma with supraclavicular lymph node only
  • Is deemed suitable for dCRT
  • Is ineligible for curative surgery based on the documented opinion of a qualified medical/surgical/radiation oncologist.
  • Is not expected to require tumor resection during the course of the study
  • Has an (ECOG) performance status of 0 to 1 within 3 days of the first dose of study treatment
  • Has adequate organ function
  • Male participants must use adequate (a male condom plus partner use of an additional contraceptive method) unless confirmed to be azoospermic (vasectomized or secondary to medical cause) and refrain from donating sperm during the study treatment period and through 90 days after the last dose of chemotherapy
  • Female participants who are a Woman of (WOCBP) must use contraception that is highly effective (with a failure rate of \<1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle, during the study treatment period through 180 days after the last dose of chemotherapy or 120 days after the last dose of pembrolizumab, whichever is greater, and agree not to donate eggs to others or freeze/store for her own use for the purpose of reproduction during this period
  • Female participants must not be pregnant or breastfeeding

Exclusion criteria

Exclusion Criteria:

  • Has direct invasion of tumor into adjacent organs such as the aorta or trachea or has radiographic evidence of >90 degree encasement or invasion of a major blood vessel, or of intratumoral cavitation
  • Has had major surgery other than for insertion of a feeding tube, open , or significant traumatic injury within 28 days prior to randomization, or anticipates the need for major surgery during study treatment; participants with gastric or esophageal fistulae are excluded
  • Has had weight loss of >20% in the previous 3 months
  • Has had prior chemotherapy or radiotherapy for esophageal cancer
  • Has had a myocardial infarction within the past 6 months
  • Has symptomatic congestive heart failure
  • Has received prior therapy with an anti-programmed cell death-1 (), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-programmed cell death-ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137)
  • Has received a live or within 30 days prior to the first dose of study intervention; administration of killed vaccines is allowed
  • Has received any prior systemic anticancer therapy for esophageal cancer including agents
  • Has not recovered from all adverse events (AEs) due to previous non-anticancer therapies to ≤Grade 1 or Baseline
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy or any other form of therapy within 7 days prior the first dose of study treatment
  • Has a known additional that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded from the study. Participants with localized prostate cancer that has undergone potentially curative treatment can be enrolled in the study.
  • Has severe (≥Grade 3) to pembrolizumab, any of the study chemotherapy agents, or their
  • Has an active disease that has required systemic treatment in past 2 years
  • Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
  • Has an active infection requiring systemic therapy
  • Has a known history of (HIV) infection
  • Has a known history of or known active virus infection
  • Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
  • Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment (180 days for participants receiving cisplatin who are breastfeeding)
  • Has had an allogeneic tissue/solid organ transplant
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
703 participants (actual)

Study arms

  • Experimental
    Pembrolizumab+FP or FOLFOX Therapy+Radiotherapy

    Participants receive pembrolizumab 200 mg on Day 1 of each 3-week cycle for 8 cycles followed by pembrolizumab 400 mg on Day 1 of each 6-week cycle for 5 cycles PLUS either: * FP therapy: cisplatin 75 mg/m\^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-fluorouracil (5-FU)\] 1000 mg/m\^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m\^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gray \[Gy\] in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR * FOLFOX therapy: oxaliplatin 85 mg/m\^2 AND either leucovorin 400 mg/m\^2 OR levoleucovorin 200 mg/m\^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m\^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m\^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle. All treatments except radiotherapy are given by intravenous (IV) infusion. Total treatment duration is approximately 1 year.

    Biological: pembrolizumab · Drug: cisplatin · Drug: 5-FU · Radiation: radiotherapy · Drug: leucovorin · Drug: levoleucovorin · Drug: oxaliplatin

  • Placebo comparator
    Placebo+FP or FOLFOX Therapy+Radiotherapy

    Participants receive placebo on Day 1 of each 3-week cycle for 8 cycles followed by placebo on Day 1 of each 6-week cycle for 5 cycles PLUS either: * FP therapy: cisplatin 75 mg/m\^2 on Day 1 of Weeks 1, 5, 8 and 11 PLUS 5-FU 1000 mg/m\^2 per day on Days 1-4 of Weeks 1, 5, 8 and 11 OR 800 mg/m\^2/day on each of Days 1-5 at Weeks 1, 5, 8, and 11 PLUS radiotherapy (either 50 Gy in 25 fractions OR 60 Gy in 30 fractions) on Days 1-5 of each 3-week cycle OR * FOLFOX therapy: oxaliplatin 85 mg/m\^2 AND either leucovorin 400 mg/m\^2 OR levoleucovorin 200 mg/m\^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 PLUS either 5-FU 400 mg/m\^2 on Day 1 of Weeks 1, 3, 5, 7, 9 and 11 OR 5-FU 800 mg/m\^2 per day on Days 1 and 2 of Weeks 1, 3, 5, 7, 9 and 11 PLUS radiotherapy (50 Gy in 25 fractions) on Days 1-5 of each 3-week cycle. All treatments except radiotherapy are given by IV infusion. Total treatment duration is approximately 1 year.

    Drug: placebo · Drug: cisplatin · Drug: 5-FU · Radiation: radiotherapy · Drug: leucovorin · Drug: levoleucovorin · Drug: oxaliplatin

Interventions

  • Biologicalpembrolizumab

    IV infusion

    Also known as: MK-3475, KEYTRUDA®

  • Drugplacebo

    IV infusion

    Also known as: Normal saline solution

  • IV infusion

    Also known as: PLATINOL®

  • Drug5-FU

    IV infusion

    Also known as: ADRUCIL®

  • Radiationradiotherapy

    external radiation

  • IV infusion

    Also known as: calcium folinate, folinic acid

  • IV infusion

    Also known as: FUSILEV®, calcium levofolinate, levofolinic acid

  • IV infusion

    Also known as: ELOXATIN®

06

What researchers measure

Primary outcomes

  1. Event-free Survival (EFS)

    EFS is defined as the time from randomization to an event defined as local, regional, or distant radiological recurrence as assessed by the investigator; clinical recurrence as assessed by the investigator with histopathologic confirmation (in the absence of radiological disease recurrence by investigator assessment); or death from any cause, whichever occurs first.

    Time frame: Up to ~60 months

  2. Overall Survival (OS)

    OS is defined as the time from randomization to death from any cause.

    Time frame: Up to ~72 months

Secondary outcomes

  1. Number of participants with an adverse event (AE)

    An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to ~15 months

  2. Number of participants discontinuing study treatment due to an adverse event (AE)

    An AE is any untoward medical occurrence in a participant that is temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Up to ~12 months

07

Study locations

170 sites
  • MemorialCare Health System - Long Beach Medical Center-Oncology ( Site 0691)
    Long Beach, California 90806, United States
  • Columbus Regional Research Institute ( Site 0047)
    Columbus, Georgia 31904, United States
  • University of Kansas Cancer Center ( Site 0023)
    Westwood, Kansas 66205, United States
  • Cancer Center of Kansas ( Site 0058)
    Wichita, Kansas 67214, United States
  • University Medical Center ( Site 0035)
    New Orleans, Louisiana 70112, United States
  • Greater Baltimore Medical Center ( Site 0031)
    Baltimore, Maryland 21204, United States
  • Dana Farber Cancer Center ( Site 0034)
    Boston, Massachusetts 02215, United States
  • Henry Ford Hospital ( Site 0685)
    Detroit, Michigan 48202, United States
  • University of Missouri ( Site 0688)
    Columbia, Missouri 65212, United States
  • Renown Regional Medical Center ( Site 0706)
    Reno, Nevada 89502, United States
  • Rutgers Cancer Institute of New Jersey ( Site 0695)
    New Brunswick, New Jersey 08903, United States
  • Weill Cornell Medical College ( Site 0053)
    New York, New York 10065, United States
  • Stephenson Cancer Center ( Site 0044)
    Oklahoma City, Oklahoma 73104, United States
  • Oregon Health & Science University Center for Health & Healing 2- CHH2 ( Site 0060)
    Portland, Oregon 97239, United States
  • Allegheny Health Network ( Site 0042)
    Pittsburgh, Pennsylvania 15212, United States
  • Thompson Cancer Survival Center ( Site 0696)
    Knoxville, Tennessee 37916, United States
  • Utah Cancer Specialists ( Site 0697)
    Salt Lake City, Utah 84106, United States
  • Cancer Care Northwest - Spokane Valley ( Site 0036)
    Spokane Valley, Washington 99216, United States
  • University of Wisconsin Hospital and Clinics ( Site 0033)
    Madison, Wisconsin 53792, United States
  • Instituto Medico Alexander Fleming ( Site 0063)
    Buenos Aires, Buenos Aires F.D. C1426ANZ, Argentina
  • Fundacion Favaloro ( Site 0061)
    Ciudad de Buenos Aires, Buenos Aires F.D. C1093AAS, Argentina
  • Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0066)
    Buenos Aires, C1264AAA, Argentina
  • CEMIC ( Site 0064)
    Buenos Aires, C1431FWO, Argentina
  • UCL Saint Luc ( Site 0162)
    Brussels, Bruxelles-Capitale, Region de 1200, Belgium
  • UZ Gent ( Site 0163)
    Ghent, Oost-Vlaanderen 9000, Belgium
  • UZ Leuven ( Site 0161)
    Leuven, Vlaams-Brabant 3000, Belgium
  • AZ Delta ( Site 0165)
    Roeselare, West-Vlaanderen 8800, Belgium
  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0088)
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Hospital Nossa Senhora da Conceicao ( Site 0087)
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Clinica de Oncologia Reichow ( Site 0085)
    Blumenau, Santa Catarina 89010-340, Brazil
  • Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0081)
    São Paulo, 01246-000, Brazil
  • Cross Cancer Institute ( Site 0010)
    Edmonton, Alberta T6G 1Z2, Canada
  • CancerCare Manitoba ( Site 0002)
    Winnipeg, Manitoba R3E 0V9, Canada
  • The Ottawa Hospital - Cancer Care ( Site 0008)
    Ottawa, Ontario K1H 8L6, Canada
  • Sunnybrook Research Institute ( Site 0012)
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre ( Site 0011)
    Toronto, Ontario M5G 2M9, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0005)
    Montreal, Quebec H2X 0A9, Canada
  • Centro Investigación del Cáncer James Lind ( Site 0106)
    Temuco, Araucania 4800827, Chile
  • Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0103)
    Temuco, Araucania 4810218, Chile
  • Hospital Regional de Concepcion ( Site 0105)
    Concepción, Biobio 4070038, Chile
  • Centro de Cancer Nuestra Senora de la Esperanza ( Site 0104)
    Santiago, Region M. de Santiago 8330024, Chile
  • Anhui Provincial Hospital-Oncology Radiotherapy Department ( Site 0531)
    Hefei, Anhui 230071, China
  • The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Si
    Fuzhou, Fujian 350025, China
  • The First Affiliated Hospital of Xiamen University ( Site 0538)
    Xiamen, Fujian 361003, China
  • Hubei Cancer Hospital ( Site 0514)
    Wuhan, Hubei 430079, China
  • Hunan Cancer Hospital ( Site 0515)
    Changsha, Hunan 410006, China
  • Huai an First People s Hospital ( Site 0526)
    Huai'an, Jiangsu 223001, China
  • Jiangsu Cancer Hospital ( Site 0519)
    Nanjing, Jiangsu 210000, China
  • The Affiliated Hospital of Xuzhou Medical University ( Site 0522)
    Xuzhou, Jiangsu 221002, China
  • Affiliated Hospital of Jiangsu University ( Site 0524)
    Zhenjiang, Jiangsu 212000, China
  • Jiangxi Cancer Hospital ( Site 0512)
    Nanchang, Jiangxi 330029, China
  • Shanghai Chest Hospital ( Site 0501)
    Shanghai, Shanghai Municipality 200030, China
  • Shanghai Chest Hospital ( Site 0503)
    Shanghai, Shanghai Municipality 200030, China
  • Zhongshan Hospital Fudan University ( Site 0502)
    Shanghai, Shanghai Municipality 200032, China
  • Sichuan Cancer Hospital ( Site 0527)
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University Cancer Institute & Hospital ( Site 0505)
    Tianjin, Tianjin Municipality 300060, China
  • Hangzhou First People's Hospital ( Site 0530)
    Hangzhou, Zhejiang 310002, China
  • Sir Run Run Shaw Hospital ( Site 0523)
    Hangzhou, Zhejiang 310018, China
  • Zhejiang Cancer Hospital ( Site 0529)
    Hangzhou, Zhejiang 310022, China
  • Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0721)
    Brno, Brno-mesto 656 53, Czechia
  • Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 0719)
    Ostrava, Moravian-Silesian Region 708 52, Czechia
  • Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0720)
    Olomouc, Olomouc Region 779 00, Czechia
  • Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0718)
    Prague, Praha 5 150 06, Czechia
  • Rigshospitalet ( Site 0199)
    Copenhagen, Capital Region 2100, Denmark
  • Odense Universitetshospital ( Site 0200)
    Odense, Region Syddanmark 5000, Denmark
  • SA Pohja-Eesti Regionaalhaigla ( Site 0201)
    Tallinn, Harju 13419, Estonia
  • SA Tartu Ulikooli Kliinikum ( Site 0202)
    Tartu, Tartu 50406, Estonia
  • Institut De Cancerologie De Lorraine ( Site 0222)
    Vandœuvre-lès-Nancy, Ain 54519, France
  • Centre Francois Baclesse ( Site 0236)
    Caen, Calvados 14075, France
  • Centre Georges Francois Leclerc ( Site 0223)
    Dijon, Cote-d Or 21079, France
  • CHU Limoges Hopital Dupuytren ( Site 0225)
    Limoges, Haute-Vienne 87042, France
  • Institut Curie - Centre Rene Huguenin ( Site 0237)
    Saint-Cloud, Hauts-de-Seine 92210, France
  • Institut Jean Godinot ( Site 0238)
    Reims, Marne 51726 CEDEX, France
  • CHU Hotel Dieu Nantes ( Site 0230)
    Nantes, Pays de la Loire Region 44093, France
  • Institut Sainte Catherine ( Site 0228)
    Avignon, Provence-Alpes-Côte d'Azur Region 84918, France
  • CHU Amiens Picardie Site Sud Amiens ( Site 0235)
    Amiens, Somme 80054, France
  • CHD Vendee ( Site 0227)
    La Roche-sur-Yon, Vendee 85925, France
  • Marienhospital Stuttgart Vincenz von Paul Kliniken gGmbH ( Site 0253)
    Stuttgart, Baden-Wurttemberg 70199, Germany
  • Universitaetsklinikum Koeln ( Site 0251)
    Cologne, North Rhine-Westphalia 50937, Germany
  • Universitaetsklinikum Muenster ( Site 0248)
    Münster, North Rhine-Westphalia 48149, Germany
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz ( Site 0247)
    Mainz, Rhineland-Palatinate 55131, Germany
  • Charite Campus Virchow Klinikum ( Site 0250)
    Berlin, 13353, Germany
  • Facharztzentrum Eppendorf ( Site 0242)
    Hamburg, 20249, Germany
  • Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0122)
    Guatemala City, 01010, Guatemala
  • Gastrosoluciones ( Site 0126)
    Guatemala City, 01010, Guatemala
  • Oncomedica ( Site 0125)
    Guatemala City, 01010, Guatemala
  • Grupo Medico Angeles ( Site 0121)
    Guatemala City, 01015, Guatemala
  • Medi-K Cayala ( Site 0124)
    Guatemala City, 01016, Guatemala
  • Centro Medico Integral De Cancerología (CEMIC) ( Site 0123)
    Quetzaltenango, 09002, Guatemala
  • Pamela Youde Nethersole Eastern Hospital ( Site 0543)
    Hong Kong, Hong Kong
  • Princess Margaret Hospital. ( Site 0542)
    Hong Kong, Hong Kong
  • Queen Mary Hospital ( Site 0541)
    Pokfulam, Hong Kong
  • Pecsi Tudomanyegyetem AOK ( Site 0265)
    Pécs, Baranya 7624, Hungary
  • Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 0262)
    Gyula, Bekes County 5700, Hungary
  • Orszagos Onkologiai Intezet ( Site 0263)
    Budapest, 1122, Hungary
  • Debreceni Egyetem Klinikai Kozpont ( Site 0261)
    Debrecen, 4032, Hungary
  • Fondazione IRCCS Policlinico San Matteo-Oncology ( Site 0300)
    Pavia, Lombardy 27100, Italy
  • IRCCS Policlinico San Donato ( Site 0295)
    San Donato Milanese, Milano 20097, Italy
  • Azienda Ospedaliero Universitaria Pisana - Presidio Santa Chiara ( Site 0294)
    Pisa, Tuscany 56126, Italy
  • ASST Papa Giovanni XXIII ( Site 0296)
    Bergamo, 24127, Italy

Showing the first 100 of 170 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, Mamon HJ, Moehler M, Fu X, Cho BC, Bordia S, Bhagia P, Shih CS, Desai A, Enzinger P. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol. 2021 Apr;17(10):1143-1153. doi: 10.2217/fon-2020-0969. Epub 2021 Feb 3. PubMed 33533655 ↗

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2020 to primary completion in Jan 2026, 70 months.

Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's 70 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2019
First posted
Dec 24, 2019
StartActual
Feb 28, 2020
Primary completionActual
Jan 21, 2026
CompletionActual
Jun 26, 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Jun 23, 2026→Jun 26, 2026
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Study completion Jun 23, 2026→Jun 26, 2026
    + 4 other changes: identifiers, verification date, site details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04210115
Responsible party
Sponsor
First posted
Dec 24, 2019
Start date
Feb 28, 2020
Primary completion
Jan 21, 2026
Completion
Jun 26, 2026
Last update
Oct 30, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion